Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Nuvalent's promising lead candidates and strong investor interest has put the stock under the spotlight. Read more about the ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...

Kendra L. Sweet, MD, a SWOG investigator at Moffitt Cancer Center, reports results of the SWOG S1712 clinical trial at the ESH-iCMLf John Goldman Conference on CML in Prague, September 27th. The phase ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

Keywords: Covalent inhibitors, Protein tyrosine kinases, Cancer, Neurodegenerative disorders, Undruggable proteins Important Note: All contributions to this Research Topic must be within the scope of ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Chronic Myeloid Leukemia (CML) affects millions worldwide, including a rising number in India. Effective management involves ...

ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.